Novartis Teams Up With Legend, Moving CAR-T Into Solid Tumors

 
• By Alaric DeArment
  
Novartis signed a licensing deal with Legend Biotech for its DLL3-directed CAR-T therapy candidates. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business